Top in hem/onc: Hormone therapy and breast cancer recurrence; rise in rare malignancy
Click Here to Manage Email Alerts
A recent study showed that menopausal hormone therapy or vaginal estrogen therapy did not increase the risk for breast cancer recurrence among postmenopausal women with early-stage, ER-positive disease.
However, researchers observed an increased risk for recurrence among women who received vaginal estrogen therapy with adjuvant aromatase inhibitors. It was the top story in hematology/oncology last week.
The second top story was about a rapid increase in anaplastic large-cell lymphoma of the breast — a rare malignancy identified as a potential adverse effect of breast implants — in the United States.
Read these and more top stories in hematology/oncology below:
Menopausal hormone therapy not associated with breast cancer recurrence, mortality.
Menopausal hormone therapy or vaginal estrogen therapy did not appear to be associated with an increased risk for breast cancer recurrence or mortality among postmenopausal women with early-stage, ER-positive disease, according to study results. Read more.
Incidence of lymphoma subtype linked to breast implants rises rapidly in US
Age-adjusted incidence of anaplastic large-cell lymphoma of the breast rapidly increased in the U.S. between 2000 and 2018, according to a research letter published in JAMA Oncology. Read more.
Marital status may predict long-term survival in early-stage gastric cancer
Being married may increase the chances of long-term survival among patients with early-stage gastric cancer, according to research published in Journal of Investigative Medicine. Read more.
Investigational compound shows ‘very dramatic’ capability to enhance CAR T-cell efficacy
Researchers have developed a genetically modified form of the immune-stimulating protein interleukin-7 that significantly enhanced chimeric antigen receptor T-cell therapy activity in preclinical testing. Read more.
Role of circulating tumor DNA in lung cancer detection, treatment 'exciting' for field
Within the past decade, data have emerged indicating an effective role of circulating tumor DNA in identifying lung cancer at an early stage and in matching patients with appropriate treatments. Read more.